22. Danaher (DHR)
Number of Hedge Funds: 125 (2025Q4)
Number of Hedge Funds: 117 (2025Q3)
As of March 2, 2026, Danaher Corporation (DHR) remains a top-tier institutional favorite, though its stock performance has faced some recent volatility. Based on the data from the Insider Monkey page, here is the analysis of what the “smart money” and the company’s leadership are doing:
1. Institutional & Hedge Fund Sentiment
Hedge funds are maintaining significant exposure to Danaher, viewing it as a core “high-moat” compounder in the life sciences and diagnostics space.
- The “Bull Case” Reiteration: In February 2026, Heavy Moat Investments published a bullish thesis on Danaher, highlighting the company’s superior capital allocation and its “compelling” valuation following recent market digestion.
- Jim Cramer’s “Game Plan”: Danaher was recently featured in Jim Cramer’s “Weekly Game Plan” as a stock to watch during earnings season. It is currently viewed by many as a “stable” bet during periods of macroeconomic uncertainty.
- Smart Money Concentration: Institutional investors continue to anchor the stock, with a consensus focus on Danaher’s post-spinoff focus (after the Veralto and Envista splits) as a pure-play life sciences powerhouse.
2. The Fundamental Outlook (2026)
The institutional interest is supported by a strong start to the year:
- Q4 2025 Earnings: Danaher’s latest earnings call (January 29, 2026) signaled a stabilizing bioprocessing market, which had been a headwind for much of the previous year.
- Cash Flow Dominance: Hedge funds are particularly attracted to Danaher’s “DBS” (Danaher Business System) culture, which has historically allowed the company to generate massive free cash flow for further M&A activities.
3. Insider Trading: Coordinated February Activity
The “Insider Roster” shows a massive, synchronized wave of activity in late February 2026. This level of participation from the entire senior leadership team suggests a major vesting and tax-planning event following the fiscal year-end.
Key Insiders Active (Feb 19–27, 2026):
- Mitchell Rales (Chairman, Exec. Committee): Active on Feb 27, 2026.
- Rainer Blair (President & CEO): Active on Feb 6, 2026.
- Matthew McGrew (EVP & CFO): Active on Feb 6, 2026.
- C-Suite Presence: Nearly the entire executive team—including the Chief Science Officer, Chief Legal Officer, Chief Accounting Officer, and several Executive Vice Presidents—had active filings in February.
Specific Transaction Highlight:
- Gregory Milosevich (EVP): Sold 1,320 shares on February 19, 2026, at $208.01.
- Matthew McGrew (CFO): Executed a significant sale of over 16,000 shares in late 2025 at $214.62.
Summary Verdict
Danaher is currently in a “Value-Growth Consolidation” phase. While the stock has faced some price pressure (trading near the $208–$214 level where insiders have been selling), the institutional “smart money” remains overwhelmingly bullish on the company’s long-term moat. The heavy insider activity in February 2026 is largely programmatic, reflecting a leadership team that is deeply integrated into the company’s equity structure as they navigate the 2026 bioprocessing recovery.
